e-Therapeutics to collaborate with Intellegens and Biorelate to enhance and extend its AI technology capabilities

e-Therapeutics is to collaborate with Intellegens and Biorelate to enhance and extend its artificial intelligence technology capabilities. 

e-Therapeutics said both companies had artificial intelligence (AI) tools which, after pilot studies, had been proven to enhance e-Therapeutics' existing computational NDD technology. 

No financial details were disclosed. Intellegens is a spin-out from the University of Cambridge that has developed a unique AI method for training neural networks from incomplete data. 

e-Therapeutics said the collaboration will allow it to apply Intellegens' technology to the predication and error correction of large-scale biological and chemical data. 

It said this would enable neural networks to be trained on the sparse data typical of biological and chemical problems. Application of the technology will result in the enhancement of e-Therapeutics' existing proprietary databases facilitating greater coverage of chemical space. In addition, it will be used to develop a novel computationally guided approach to medicinal chemistry. Manchester-based Biorelate provides biomedical knowledge by using AI to create curated databases from the analysis of published literature. 

Its cutting edge technology uniquely combines natural language processing (NLP) and machine learning with human expert curation. The result is the extraction of structured biological knowledge from the wide body of expert journals. 

e-Therapeutics said aim of the collaboration was to directly feed this knowledge into its Network-Driven Drug Discovery engine facilitating the pursuit of novel disease mechanisms.